Racura Oncology Ltd · ASX:RAC
Racura Oncology — Investor Presentation (November 2026)
18 slides from Racura Oncology's investor presentation, Nov 19, 2026
Slide 1: EMILI Trial Snapshot – Investor Webinar
personal use only INVESTOR WEBINAR · 19 NOVEMBER 2026 EMILI TRIAL SNAPSHOT MILESTONE ACHEIVED Sheba Medical Center ethics approval (18 November 2026) PRINCIPAL INVESTIGATOR Evaluation of a MYC-silencing Intervention in Acute Myeloid LeukemIa Professor Arnon Nagler (Sheba, Israel) RC220 in relapsed o
Slide 2: Important notice and disclaimer
IMPORTANT NOTICE Important notice and disclaimer personal use only 01 · DI SCLOSURE BASI S 02 · ESTI MATES & RI SKS Summary information Forward-looking statements Prepared by Racura Oncology Limited (ASX: RAC; “Racura” or the Includes statements on ethics and regulatory approvals, site “Company”). C
Slide 3: Sheba ethics approval moves EMILI toward first patient
18 NOVEMBER MILESTONE Sheba ethics approval moves EMILI toward first patient personal use only LE A D C LI N I C A L S I T E Sheba Medical Center, Israel · PR I N C I PA L I N V E S T I G A T OR Prof. Arnon Nagler (AML & transplant clinician-scientist) 01 NOV 2026 02 Q1 2027 (EST.) 03 PLANNED 2027 E
Slide 4: Relapsed or refractory AML remains an area of acute unmet need
THE DISEASE Relapsed or refractory AML remains an area of acute unmet need personal use only What is acute myeloid leukemia (AML)? An aggressive, fast-growing cancer of the blood and bone marrow. Immature white blood cells rapidly accumulate and crowd out healthy blood cells, causing life-threatenin
Slide 5: The clinical goal in relapsed AML
THE PATIENT REALITY The clinical goal in relapsed AML personal use only For patients with relapsed AML, the main curative option is an allogeneic stem cell transplant1. But first, their leukemia must be brought under control. WITHOUT REMISSION (ACTIVE DISEASE) WITH REMISSION + TRANSPLANT FITNESS Pat
Slide 6: The critical hurdle: from relapse to transplant eligibility
THE CRITICAL HURDLE The critical hurdle: from relapse to transplant eligibility personal use only 01 STARTING POINT 02 THE BRIDGE 03 CURATIVE GOAL Relapsed or refractory Remission hurdle (CR/CRi) Allo-HSCT (donor AML transplant) Disease has returned after initial → Leukemia blasts must be cleared to
Slide 7: How RC220 aims to address key gaps in R/R AML
CLINICAL POSITIONING How RC220 aims to address key gaps in R/R AML personal use only SALVAGE CHEMOTHERAPY TARGETED AGENTS WHAT EMILI IS TESTING Intensive cytotoxic salvage Mutation-specific inhibitors RC220: G4 MYC gene strategy REACH REACH BIOLOGICAL RATIONALE Broadly used across R/R AML patients f
Slide 8: MYC acts as a master switch for cancer cell growth
THE BIOLOGICAL TARGET MYC acts as a master switch for cancer cell growth personal use only H E A LT H Y C E LL ON ONLY WHEN NEEDED C A N C E R C E LL STUCK ON MYC is tightly controlled Persistent, unchecked proliferation In normal cells, MYC transcription switches on briefly to Extra gene copies, ch
Slide 9: Why MYC remained out of reach for conventional drugs
THE 40-YEAR “UNDRUGGABLE” STATUS Why MYC remained out of reach for conventional drugs personal use only 40 years THE STRUCTURAL REALITY The MYC–MAX heterodimer grips DNA across a flat, pocketless coiled-coil interface. Targeting the upstream MYC DNA promoter bypasses this of research, and still no u
Slide 10: (E,E)-bisantrene turns down MYC at the gene, not the protein
RACURA’S APPROACH (E,E)-bisantrene turns down MYC at the gene, not the protein personal use only THE USUAL APPROACH RACURA’ S MECHANISM Block the disordered MYC protein after it has already been Bind G-quadruplex (G4) DNA in the MYC gene promoter to reduce produced. transcription. DNA FOLDING SWITCH
Slide 11: AML is the right place to test MYC silencing in patients
WHY AML AML is the right place to test MYC silencing in patients personal use only MYC drives AML biology MYC expression across WHO AML subtypes ~90% MYC protein is overexpressed in ~90% of newly diagnosed AML patients, sustaining leukemia stem-cell self-renewal; higher levels associated with poorer
Slide 12: Prior AML activity; RC220 is designed for peripheral IV
CLINICAL FOUNDATION & FORMULATION Prior AML activity; RC220 is designed for peripheral IV personal use only 1988 4 / 10 (40%) 6 / 15 (40%) French AML approval Sheba Phase 2 monotherapy (RC110) Sheba Phase 1b/2 combination Earlier bisantrene formulation approved in France for AML with an objective re
Slide 13: EMILI: seamless Phase 2b/3 designed for FDA Project Optimus
TRIAL DESIGN EMILI: seamless Phase 2b/3 designed for FDA Project Optimus personal use only ELIGIBLE PATIENTS Adults 18–78 years with R/R AML, ≤3 prior regimens, allo-HSCT candidates. TREATMENT REGIMEN Single 7-day cycle of RC220: 2-hour peripheral IV once daily, Days 1–7. PHASE 2b Up to 68 patients:
Slide 14: Adaptive design built to select the optimal dose efficiently
PHASE 2b MECHANISM Adaptive design built to select the optimal dose efficiently personal use only STEP 1 · LEAD-IN STEP 2 · ADAPTIVE GATE STEP 3 · DOSE SELECTION 6 patients at 175 mg/m² Randomize 62 patients (1:1) Select RP3D for Phase 3 Safety Review Committee (SRC) assesses → Depending on the lead
Slide 15: What Phase 2b will evaluate and report to investors
READOUTS & TRANSLATIONAL VALUE What Phase 2b will evaluate and report to investors personal use only CLINICAL ENDPOINTS TRANSLATIONAL SCIENCE Clinical & dose-selection readouts MYC biomarkers & pipeline Remission rates by dose arm relevance Rates of complete remission (CR) and complete remission wit
Slide 16: Milestones from Sheba ethics approval to Phase 2b readout
EXECUTION ROADMAP Milestones from Sheba ethics approval to Phase 2b readout personal use only NOV 2026 UNDERWAY BY END 2026 Q1 2027 UPCOMING Ethics approved Site governance Trial initiation First patient CRO, registry & global sites Sheba Helsinki Sheba contractual, Governance completion, First pati
Slide 17: Why EMILI matters for Racura investors
INVESTMENT CASE Why EMILI matters for Racura investors personal use only 01 DUAL CLINICAL + BIOMARKER OBJECTIVE 02 CAPITAL & TIME EFFICIENCY Two core questions in one trial Seamless Phase 2b/3 efficiency Tests whether a single 7-day course of RC220 can bridge One protocol transitions Phase 2b into c
Slide 18: Questions & Discussion
personal use only RACURA ONCOLOGY · ASX: RAC Questions & Discussion Ethics approved at Sheba · First patient expected Q1 2027 WEBI NAR SPEAKERS & LEAD SI TE CLI NI CAL & I NVESTOR ENQUI RI ES Dr Daniel Tillett — Chief Executive Officer & Managing Director Trial enquiries: trials@racuraoncology.com D
Racura Oncology — Investor Presentation (November 2026) on 6ix